La digitalizzazione a supporto del processo di implementazione del nuovo modello di assistenza territoriale della ASL di Sassari

L’emergenza pandemica ha accelerato l’adozione delle tecnologie digitali e il potenziamento dell’assistenza territoriale. Il contributo analizza come la ASL di Sassari stia gestendo il processo di digitalizzazione e innovazione dei servizi territoriali, sulla spinta del PNRR e secondo i criteri del DM 77/2022 e delle direttive regionali. Il caso studio è particolarmente rilevante in quanto l’azienda è chiamata a gestire massicci investimenti e profondi cambiamenti di sistema, all’interno di una fase estremamente complessa, derivante dalla riforma regionale in atto e dal conseguente disallineamento dei processi istituzionali, organizzativi e tecnologici. Il lavoro evidenzia come la ASL di Sassari si trovi davanti a una duplice sfida: implementare in modo efficace e rapido le strategie del PNRR, secondo un approccio top-down; sviluppare dal basso l’innovazione dei servizi territoriali collegati all’uso delle nuove tecnologie digitali e al nuovo modello di medicina di prossimità.The pandemic emergency has accelerated the adoption of digital technologies and the innovation of territorial assistance. The paper explores how the Sassari Health Care Organization (HCO) is managing the digitalization and community care reorganizational process, according to the Ministerial Decree 77/2022 criteria and regional directives. In the light of recent Sardinia health care system reform, Sassari HCO represents a relevant example of how the organization is called to manage the PNRR funds within an extremely complex context, deriving from the misalignment of institutional, organizational and technological processes. The case study highlights how Sassari HCO is facing with a double challenge: implementing effectively and quickly the PNRR strategic investments, according to top-down boost; developing, through a bottom-up approach, the innovation of its health services linked to new digital technologies and primary care design

Intimate Partner Violence and Cervical Neoplasia

Intimate partner violence (IPV) is associated with a range of adverse physical health outcomes, including chronic and infectious diseases. An emerging literature suggests that partner violence and specifically sexual violence may be associated with an increased risk of cervical neoplasia. To assess the risk of preinvasive and invasive cervical cancer in a cross-sectional study of women screened for IPV by type, frequency and duration, 1152 women ages 18–65 were recruited from family practice clinics in 1997–1998. They were screened for IPV during a brief in-clinic interview, and health history and current status were assessed in a follow-up interview. Of 1152 women surveyed, 14 (1.2%) reported cervical cancer, and 20.3% (n 5 234) reported treatment for cervical neoplasia. Ever experiencing IPV was associated with an increased risk of invasive cervical cancer (adjusted relative risk [aRR] 5 4.28; 95% CI 1.94, 18.39) and with preinvasive cervical neoplasia (aRR 5 1.47; 95% CI 1.16, 1.82). This association was stronger for women experiencing physical or sexual IPV than for women experiencing psychological IPV. Women with cervical cancer reported being in violent relationships longer and experiencing more frequent physical and sexual assaults and more IPV-associated injuries than did controls. This exploratory study suggests that IPV may increase a woman’s risk of cervical neoplasia. The mechanism by which IPV affects cervical neoplasia may be indirect through psychosocial stress or negative coping behaviors or direct through sexual assaults and transmission of human papillomavirus (HPV)

Hormonal and Barrier Methods of Contraception, Oncogenic Human Papillomaviruses, and Cervical Squamous Intraepithelial Lesion Development

We assessed the influence of hormonal (oral, injectable, or levonorgestrel [Norplant, Wyeth-Ayerst, Philadelphia, PA]) and barrier methods of contraception on the risk of cervical squamous intraepithelial lesions (SIL), while adjusting for high-risk (HR) HPV infection. Subjects were women receiving family planning services through the state health department clinics from 1995 to 1998. We selected 60 cases with high-grade cervical/SIL (HSIL) and 316 with low-grade cervical/SIL (LSIL) and controls (427 women with normal cervical cytology) and analyzed cervical DNA for HR-HPV, using Hybrid Capture I (Digene; Gaithersburg, MD).When assessing ever use, duration, recency, latency, and age at first use, neither oral contraceptives (OC), Norplant, nor injectable use was associated with an increased risk of SIL development after adjusting for age, age at first sexual intercourse, and HR-HPV positivity. Among HR-HPV-positive women, longer duration barrier method use was associated with a reduced risk of SIL. This finding has important clinical implications for SIL prevention among HR-HPV-infected women

Psychosocial Stress and Cervical Neoplasia Risk

OBJECTIVE: We assessed the association between psychosocial stress and preinvasive cervical neoplasia development controlling for HR-HPV infection. METHODS: This case-control study enrolled low-income women receiving family planning services at health department clinics. There were 59 cases with biopsy confirmed HSIL and 163 with low-grade SIL and 160 controls with normal cervical cytology. A modified SLE scale was used to measure stressful events and the perceived impact of the event in the prior 5 years. Unconditional logistic regression was used to assess SIL risk and stressful events scores and by subscales. RESULTS: After adjusting for age, HR-HPV infection, and lifetime number of sex partners, the SLE count score was associated with an increased risk of SIL among white women (aOR = 1.20; 95% CI = 1.04, 1.38) yet not among African American women (aOR = 1.02; 95% CI = 0.87, 1.19). The relationship stress subscale (divorce, infidelity, an increase in the number of arguments, and psychological and physical partner violence) was the only one of four subscales (loss, violence, and financial stress) associated with SIL, again, only among white women (aOR = 1.54; 95% CI = 1.21, 1.96). CONCLUSIONS: These data suggest that psychosocial stress may play a role in SIL development. Future studies are needed to confirm these findings, to explore racial difference in reporting stress, and to explore the mechanism through which psychosocial stress may affect cervical neoplasia risk

Detrimental Impact of Interferon-Based Regimens for Chronic Hepatitis C on Vitamin D/Parathyroid Hormone Homeostasis

Background: Both the anti-infective and anti-inflammatory properties of vitamin D, an essential hormone of calcium homeostasis, have ample support in the literature. The high rates of vitamin D deficiency among patients with chronic hepatitis C are also well known. That supplementation with vitamin D may boost sustained viral response rates in vitamin D deficient, hepatitis C virus (HCV) infected patients undergoing Interferon-alpha (IFN) treatment, on the other hand, is controversial. Surprisingly, studies considering in this latter setting what are the effects of IFN treatment (with or without vitamin D supplementation) on the other major regulator of mineral metabolism, i.e. the Parathyroid hormone (PTH), are lacking. Aim: Evaluate the impact of interferon-based treatment against HCV (±cholecalciferol supplementation) on vitamin D and PTH homeostasis. Methods: A series of 40 consecutive patients received pegylated IFN plus ribavirin to treat chronic hepatitis C. At the discretion of their physician, some of them (N. = 27) received vitamin D supplementation while others did not (N. = 13). All had measured plasma 25-hydroxycholecalciferol and PTH concentrations at baseline, at completion of the 4th (TW4) and 12th treatment week (TW12) and at 24 weeks after the end of therapy (SVR24). Results: Plasma PTH concentration increased significantly from baseline during treatment, raising to 44.8 [30.7-57.2] pg/mL at TW4 (p=0.01), 47.0 [37.1-63.2] pg/mL at TW12 (p=0.006) to return to baseline levels in the follow-up (34.5 [27.6-43.0]; p=0.16). The proportion of patients who satisfied criteria for hyperparathyroidism was higher at TW12 (N=10, 25%) than at TW4 (N=6, 15%). There was no statistical correlation between vitamin D and PTH blood levels (ρ=-0.07; p=0.65). Conclusion: An increase in plasma PTH occurs systematically during IFN treatment of HCV patients and cannot be prevented by vitamin D supplementation

Targeting CD20 in the treatment of interstitial lung diseases related to connective tissue diseases: A systematic review

INTRODUCTION: The effectiveness of CD20 targeting in connective tissue diseases (CTD) with lung involvement is controversial. This paper aims to review the current evidence about rituximab (RTX) use in CTD-related interstitial lung disease (ILD). METHODS: We performed a systematic review of papers published between January 2009 and May 2019. We included clinical trials, case/control studies and cohort studies. We excluded letters, case reports, case series, reviews, and full articles when not in English. The selected studies listed as primary or secondary outcome a variation in pulmonary function tests or in the scores used to radiologically stage lung involvement, in CTD-related ILD patients after RTX. RESULTS: Out of 1206 potentially eligible articles, 24 papers were selected: 3 retrospectively described cohorts of patients with different CTD, 14 dealt with systemic sclerosis (SSc)-related ILD, 5 with idiopathic inflammatory myopathies (IIMs)-related ILD, and 2 with Sjögren's Syndrome-related ILD. A direct comparison of the selected studies was hampered by their heterogeneity for outcomes, follow-up duration, the severity of lung involvement, and clinical features of study populations. However, an overall agreement existed concerning the effectiveness of RTX in the stabilization of lung disease, with some studies reporting an improvement of functional parameters from baseline. IIM-related ILD appeared more responsive than other CTD-related ILD to CD20 targeting. CONCLUSION: RTX is a promising therapeutic tool in CTD-related ILD. This systematic review remarks the unmet need of multicenter prospective studies aiming to evaluate the effectiveness of RTX with adequate sample size and study design

Modelling hospital bed necessity for COVID-19 patients during the decline phase of the epidemic trajectory

BACKGROUND: In the present study we aimed to create a model able to predict the short-term need of hospital beds for COVID-19 patients, during SARS-CoV-2 outbreak. METHODS: We retrospectively revised data about all COVID-19 patients hospitalized at a University Hospital in Northern Italy, between March 1 and April 29, 2020. Several polynomial models (from first to fourth order) were fitted to estimate the relationship between the time and the number of occupied hospital beds during the entire period and after the local peak of the outbreak and to provide the prediction of short-term hospital beds demand. Model selection was based on the adjusted R2 (aR2) Index and likelihood ratio test (LRT). RESULTS: We included 836 hospitalizations (800 COVID-19 patients). The median length of hospital in-stay was 12 days. According to the aR2, the fourth order models best fitted the data considering the entire time period. When only the data after the peak was selected, no statistical improvement was found adding terms of order 3 and 4 and lower order polynomial models were considered for the forecasting of the hospital beds demand. Both approaches had a decreasing trend in the number of occupied beds along with time; however, the quadratic one showed a faster reduction in the predicted number of beds required by patients affected by COVID-19. CONCLUSIONS: We propose a model to predict the hospital bed requirement during the descending phase of COVID-19 outbreak, the validation of which might contribute to decision makers policy in the next weeks of pandemic

Gas6/TAM system: A key modulator of the interplay between inflammation and fibrosis

Fibrosis is the result of an overly abundant deposition of extracellular matrix (ECM) due to the fact of repetitive tissue injuries and/or dysregulation of the repair process. Fibrogenesis is a pathogenetic phenomenon which is involved in different chronic human diseases, accounting for a high burden of morbidity and mortality. Despite being triggered by different causative factors, fibrogenesis follows common pathways, the knowledge of which is, however, still unsatisfactory. This represents a significant limit for the development of effective antifibrotic drugs. In the present paper, we aimed to review the current evidence regarding the potential role played in fibrogenesis by growth arrest-specific 6 (Gas6) and its receptors Tyro3 protein tyrosine kinase (Tyro3), Axl receptor tyrosine kinase (Axl), and Mer tyrosine kinase protooncogene (MerTK) (TAM). Moreover, we aimed to review data about the pathogenetic role of this system in the development of different human diseases characterized by fibrosis. Finally, we aimed to explore the potential implications of these findings in diagnosis and treatment